Hao Li

Prof. Hao Li


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
YZYi Zhang
Yi Zhang
YGYing Guo
Ying Guo
WHWenxi He
Wenxi He
YZYaping Zhao
Yaping Zhao
ZFZhaode Feng
Zhaode Feng
PLPengfei Liu
Pengfei Liu

22 April 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
WLWeiqiang Lv
Weiqiang Lv
XWXueqiang Wang
Xueqiang Wang
ZFZhaode Feng
Zhaode Feng
CSCunxiao Sun
Cunxiao Sun
HWHansen Wu
Hansen Wu
Zhihui FengZhihui Feng
Zhihui Feng
Uric acid (UA), traditionally recognized as an extracellular antioxidant, exhibits paradoxical associations with metabolic disorders such as metabolic dysfunction-associated steatotic liver disease (MASLD), though its mechanistic contributions remain elusive. Here, we integrate multi-modal evidence to explore the role of UA and its oxidative metabolite, allantoin, in MASLD progression. Analysis of UK Biobank data revealed a strong association between elevated UA levels and increased risks of MASLD and type 2 diabetes (T2D). However, Mendelian randomization analysis of over 2 million samples demonstrated causal effects of urate solely on serum triglycerides and T2D risk. Targeted metabolomics in an elderly Chinese cohort identified allantoin, an oxidative by-product of UA, significantly elevated in individuals with dyslipidemia or T2D, with serum allantoin levels positively correlated with fasting glucose, triglycerides, and cholesterol. Animal studies indicated that allantoin exacerbates hepatic lipid accumulation and glucose intolerance in high-fat diet mice, driven by increased hepatic lipid biogenesis and reduced bile acid production. Notably, further research revealed a strong binding affinity of allantoin for PPARα, leading to the suppression of PPARα activity, which promotes the progression of MASLD. These findings underscore the critical role of allantoin, rather than UA, as a critical driver of MASLD development, offering valuable insights for the prediction and management of hepatic metabolic disorders.

20 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ZFZhaode Feng
Zhaode Feng
FCFangjun Chen
Fangjun Chen
JXJiajia Xiao
Jiajia Xiao
ADAnhui Du
Anhui Du
JDJianmin Deng
Jianmin Deng
HLHao Li
Hao Li
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition that progresses from simple steatosis to advanced fibrosis, significantly affecting liver function and systemic health. Despite its widespread impact, therapeutic options are limited, highlighting the urgent need for comprehensive exploration to identify potential therapeutic targets. In this study, we created an analysis pipeline anchored on liver gene expression, integrating differential meta-analysis of transcriptomic data across three MASLD stages, transcriptome-wide Mendelian randomization (MR), and transcriptome-wide association studies (TWAS), to identify 39 candidate genes potentially involved in MASLD progression. Furthermore, we prioritized these genes using a scoring system that incorporated gene expression-clinical phenotype correlation meta-analysis, proteome-wide association studies (PWAS), and external genetic data from the GWAS Catalog and ExPheWAS. Single-nucleus RNA sequencing (snRNA-seq) analysis of liver cells from healthy to cirrhotic stages revealed stage- and cell-type-specific expression patterns of these prioritized genes. Through experimental validation in a lipid overload hepatocyte model, we confirmed the role of MLIP in lipid metabolism. These findings, available through an interactive web portal (masldportal.net), provide valuable insights into MASLD mechanisms and offer an easy-accessible resource for the research community. Graphic